No Data
No Data
BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $31
Express News | Amphastar Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $31 From $36
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating